Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

NCT07524322 is registered in ClinicalTrials.gov with Regor Pharmaceuticals Inc. as lead sponsor.

NCT NCT07524322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07524322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers
Lead sponsor
Regor Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 30, 2026
Completion date
October 31, 2028
Enrollment
63 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, cervical cancer, endometrial cancer, her2- negative breast cancer, hormone receptor positive tumor, ovarian cancer, pik3ca mutation, unresectable solid tumor